ClinicalTrials.Veeva

Menu

Local Pilocarpine for Relieving Dry Mouth

Maastricht University Medical Centre (MUMC) logo

Maastricht University Medical Centre (MUMC)

Status and phase

Completed
Early Phase 1

Conditions

Patients of Advanced Age (≥ 70 Years) With a Clinical Diagnosis of Chronic Dry Mouth

Treatments

Drug: Pilocarpine Ophthalmic Solution

Study type

Interventional

Funder types

Other

Identifiers

NCT04195100
METC18-071

Details and patient eligibility

About

The investigators intended for this study to deliver the "proof-of-concept" that locally administered pilocarpine drops in two doses are effective in a population of elderly (aged ≥ 70 years) with xerostomia at the expense of limited adverse events. To this end, the study aims to quantify the effect size of pilocarpine in two different dosages. In case the investigators observe clinically meaningful changes in xerostomia through measured NRS, a sufficiently-powered RCT will be prepared to compare pilocarpine to placebo.

Enrollment

14 patients

Sex

All

Ages

70+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • ≥ 70 years of age
  • Clinical diagnosis of chronic dry mouth defined as a Numeric Rating Scale (NRS) score ≥ 5 (scale 0 - 10, with 0 = no dry mouth and 10= worst possible dry mouth) on severity of xerostomia for more than 3 months.

Exclusion criteria

  • Existence of cognitive impairment and/or diagnosis of dementia appraised by treating physician
  • Inability to fill out the questionnaires due to other reasons
  • Prior radiation therapy of the head-and-neck region
  • Known m. Sjögren disease
  • Contra-indications for parasympathicomimetics (uncontrolled asthma, acute heart failure, active peptic ulceration, known hypersensitivity to pilocarpine, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle closure) glaucoma.

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

14 participants in 2 patient groups

Low dose pilocarpine
Active Comparator group
Description:
low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day
Treatment:
Drug: Pilocarpine Ophthalmic Solution
High dose pilocarpine
Active Comparator group
Description:
high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day
Treatment:
Drug: Pilocarpine Ophthalmic Solution

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems